Provectus Biopharmaceuticals (OTCQB: PVCT) Reports Anti-Tumor Activity of Oral PV-10 in Bladder Cancer Study

May 18, 2026

Expert Analysis Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT) continues to demonstrate promising progress in its investigational therapy portfolio with data highlighting the anti-tumor effects of its proprietary PV-10 compound. This preclinical evaluation involving oral administration of PV-10 explores a novel approach to targeting bladder cancer, a condition with significant unmet medical need. The use of an immunologically humanized mouse model provides valuable insight into the potential efficacy of PV-10, both as…

Read More >>